文献速递中枢神经肿瘤放疗头颈部肿瘤放疗泌尿生殖与妇科肿瘤放疗

再照射领域正在进行的前瞻性研究:临床试验数据库的系统综述

Ongoing prospective studies on reirradiation: A systematic review of a clinical trials database.
PubMed 文献 · Radiother Oncol · 2024-11-10

该系统综述于2024年7月11日检索ClinicalTrials.gov,纳入99项正在招募、尚未招募或活跃未招募的前瞻性再照射研究,其中40%聚焦中枢神经系统、23%头颈部、17%盆腔;90%为干预性研究,含32项II期和4项III期试验。作者结论认为仍亟需随机对照试验,尤其是肺、乳腺和妇科肿瘤领域。

要点

  • 正在进行的再照射前瞻性研究最常聚焦中枢神经系统、头颈部和盆腔部位。
  • 99项研究中干预性占90%,II期32项、III期4项,随机试验共16项。
  • 作者认为仍亟需随机对照试验,尤其是肺、乳腺和妇科肿瘤领域。

核心结论

  • 正在进行的再照射研究最常聚焦中枢神经系统、头颈部和盆腔再照射。
  • 仍亟需随机对照试验,尤其是肺、乳腺和妇科肿瘤领域。
  • 剂量递增试验、精准放疗技术应用及与现代全身治疗联合可能有助于确定最佳多模式治疗方案。

研究设计与样本

  • 于2024年7月11日对ClinicalTrials.gov进行系统综述,检索词与再照射相关。
  • 纳入标准为状态为「招募中」「尚未招募」或「活跃,未招募」的前瞻性研究,排除已发表结果、回顾性和计算机模拟研究。
  • 综述遵循PRISMA 2020指南及临床试验注册库系统检索建议。
  • 共识别1026项研究,筛选307项,最终纳入99项。

主要发现

  • 99项研究中40项(40%)聚焦中枢神经系统,23项(23%)头颈部,17项(17%)盆腔再照射。
  • 大多数研究(90%)为干预性研究,其中II期32项(32%)、III期4项(4%)。
  • 16项试验为随机对照试验,包括针对复发胶质母细胞瘤、直肠癌和鼻咽癌的4项III期试验。
  • 10项剂量递增试验聚焦复发前列腺癌、直肠癌、非小细胞肺癌及胶质瘤。
  • 21项(21%)研究使用立体定向放疗,17项(17%)使用粒子治疗;41项(41%)研究探索与全身治疗联合。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Reirradiation has gained increasing interest, as advances in systemic therapy increase the survival of patients with cancer, and modern radiation techniques allow more precise treatments. However, high-quality prospective evidence on the safety and efficacy of reirradiation to guide clinical practice remains scarce. This systematic review evaluates ongoing prospective studies on reirradiation to identify research gaps and priorities. METHODS: A systematic review of ClinicalTrials.gov was conducted on July 11, 2024, using search terms related to reirradiation. Inclusion criteria were prospective studies that were "recruiting," "not yet recruiting," or "active, not recruiting." Studies with published results, retrospective, and in-silico studies were excluded. The review followed PRISMA 2020 guidelines and recommendations for systematic searches of clinical trial registries. RESULTS: Among 1026 identified studies, 307 were screened, 99 were included. Fourty (40%) focused on central nervous system (CNS), 23 (23%) head and neck, and 17 (17%) on pelvic reirradiation. Most studies (90%) were interventional, with 32 (32%) phase II and 4 (4%) phase III trials. Sixteen trials were randomized (RCTs), including the 4 phase III trials for recurrent glioblastoma, rectal and nasopharyngeal cancer. Ten dose escalation trials focus on recurrent prostate, rectal, and non-small cell lung cancer as well as glioma. Modern high-precision radiotherapy techniques were frequently used, with 21 (21%) studies using stereotactic radiotherapy and 17 (17%) using particle therapy. Combinations with systemic therapies were investigated in 41 (41%) studies. CONCLUSION: Ongoing studies most frequently focus on CNS, head and neck, and pelvic reirradiation. There remains a critical need for RCTs, in particular for lung, breast, and gynecological cancers. Dose escalation trials, application of precision radiation techniques and combinations with modern systemic therapy may help define the optimal multimodality treatment schedules.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Willmann J, Balermpas P, Rimner A, et al. Ongoing prospective studies on reirradiation: A systematic review of a clinical trials database. Radiother Oncol. 2024. PMID: 39532233. doi:10.1016/j.radonc.2024.110624

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。